CRISPR Therapeutics AG

CRSP | NASDAQ

Price Alert Chart Builder DCF Calculator

$51.40

-$2.86 (-5.27%)

At close: Oct 30, 2026, 3:59 PM ET

$51.75

+$0.35 (+0.68%)

Pre-market: Nov 2, 2026, 9:07 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-5.27%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

33.9

+11.9 pts

Fundamentals Weak

Market Sentiment Neutral

Moat Narrow

Sector Rank #686/1028 (Top 67%)

Full Analysis

Key Statistics

Market Data

Market Cap $4.97B

1D Range

50.58 54.02

52W Range

44.34 63.99

Valuation (TTM)

PE -10.80

PB 2.85

EV/EBITDA -7.47

Valuation (NTM)

Forward PE N/A

Forward PEG 0.36

Price Target $63.17

Cash Flow

FCF Yield -9.7%

SBC Adj. FCF Yield -11.1%

SBC Impact -14.2%

Margins

Gross Margin -1534.4%

Operating Margin -3971.5%

FCF Margin -3589.7%

Growth (CAGR)

Revenue 3Y | 5Y -57.1% | -56.9%

Dil EPS 3Y | 5Y -17.1% | 12.6%

FCF 3Y | 5Y -57.1% | 2.9%

Returns

ROA -17.0%

ROE -24.4%

ROIC -21.0%

Financial Health

Net Cash

$1.78B

Current Ratio 17.85

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced ...

Sector Healthcare

Industry Biotechnology

Employees 393

IPO Date Oct 19, 2016

Website www.crisprtx.com

Fiscal Year January - December

Full Company Profile

Latest News

6 hours ago · globenewswire.com

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately.

2 days ago · zacks.com

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.

9 days ago · fool.com

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

One of CRISPR Therapeutics' leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy. The biotech could make significant clinical progress with this and other medicines over the next five years.

10 days ago · zacks.com

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.

10 days ago · zacks.com

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

12 days ago · zacks.com

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

14 days ago · globenewswire.com

CRISPR Therapeutics Announces Chief Financial Officer Transition

ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J.

15 days ago · fool.com

Where Will CRISPR Therapeutics Stock Be in 2030?

CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory progress.